Clin Psychopharmacol Neurosci.
2011 Dec;9(3):95-101.
Proteomics as a Tool for Understanding Schizophrenia
- Affiliations
-
- 1Max Planck Institute of Psychiatry, Munich, Germany and Lab. de Neurociencias (LIM-27), Inst. Psiquiatria, Fac. de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil. martins@mpipsykl.mpg.de
Abstract
- Schizophrenia is likely to be a multifactorial disorder, consequence of alterations in gene and protein expression since the neurodevelopment that together to environmental factors will trigger the establishment of the disease. In the post-genomic era, proteomics has emerged as a promising strategy for revealing disease and treatment biomarkers as well as a tool for the comprehension of the mechanisms of schizophrenia pathobiology. Here, there is a discussion of the potential pathways and structures that are compromised in schizophrenia according to proteomic findings while studying five distinct brain regions of post-mortem tissue from schizophrenia patients and controls. Proteins involved in energy metabolism, calcium homeostasis, myelinization, and cytoskeleton have been recurrently found to be differentially expressed in schizophrenia brains. These findings may encourage new studies on the understanding of schizophrenia biochemical pathways and even new potential drug targets.
